−Removed: Market for Registrant’s Common Equity, Related Stockholder
−Removed: Matters and Issuer Purchases of Equity Securities.
−Removed: Our common stock is traded
−Removed: on the Nasdaq Capital Market under the symbol “ TARA ”.
+Added: Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
+Added: common stock is traded on the Nasdaq under the symbol “ TARA ”.
Holders of Our Common Stock
−Removed: As of February 28, 2025, there were 36,767,465 shares of common stock outstanding
−Removed: held by approximately 26 stockholders of record.
−Removed: The actual number of stockholders is greater than this number of record holders, and
−Removed: includes stockholders who are beneficial owners, whose shares are held in street name by brokers and other nominees.
+Added: As of March 5, 2026, there
+Added: were 54,084,378 shares of common stock outstanding held by approximately 19 stockholders of record.
+Added: The actual number of stockholders
+Added: is greater than this number of record holders, and includes stockholders who are beneficial owners, whose shares are held in street name
+Added: by brokers and other nominees.
Dividend Policy
3 unchanged sentences
various factors, including our financial condition, operating results, anticipated cash needs and plans for expansion.
−Removed: Securities Authorized for Issuance under Equity
+Added: Authorized for Issuance under Equity Compensation Plans
+Added: Item 12 of Part III of this Annual Report on Form 10-K regarding information about securities authorized for issuance under our equity
compensation plans.
−Removed: See Item 12 of Part III of
−Removed: this Annual Report on Form 10-K regarding information about securities authorized for issuance under our equity compensation plans.
−Removed: Recent Sales of Unregistered Securities
−Removed: Common Warrant Exercises
−Removed: On December 12, 2024, 725,000 of the common warrants issued in the
−Removed: Company’s April 2024 private placement were exercised by an investor, at the exercise price of $5.25 per share, resulting in the
−Removed: issuance of 725,000 shares of the Company’s common stock.
−Removed: The securities sold in the April 2024 private placement were issued in
−Removed: reliance upon the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.
−Removed: The aggregate gross proceeds
−Removed: from the common warrant exercise was approximately $3.8 million.
−Removed: The Company intends to use the proceeds for general corporate and working
−Removed: capital purposes, including funding clinical trials.
−Removed: Not applicable.
+Added: Sales of Unregistered Securities
+Added: Purchases of Equity Securities
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.